Clinical trial data published in the New England Medical Journal on June 23, 2022, reveal that locally advanced rectal cancer stage II or III with dMMR is sensitive to drug Dostarlimab-gxly.
Read moreStudy results of Enhertu and HER-2 for Metastatic Breast Cancer
For the first time, a targeted medicine can help metastatic breast cancer patients whose tumors express only low levels of HER2.
Read moreKathy Clark to Lead Summit ReSources
Summit Reinsurance Services, Inc. has elevated Kathy Clark, RN, BSN, CMCN, to assistant vice president and director of managed care effective May 31, 2021. With this promotion, Clark assumes responsibility for Summit ReSources, Summit Re’s medical management program, and its staff.
Read moreCell and Gene Therapies: Navigating a Challenging Landscape
Cell and gene therapy will most certainly continue to shift paradigms for manufacturers, patients, healthcare providers and pharmacies for many years. These are groundbreaking technologies which offer hope to millions of individuals that previously had no viable options for treatment or cure.
Read moreKidney Disease Management Collaboration with Renalogic
Summit Reinsurance Services, Inc. announced a strategic collaboration with Renalogic, a solution provider offering risk management services for kidney disease. Renalogic uses a data-driven approach focused on predicting and preventing chronic conditions that lead to dialysis.
Read moreSpecialty Pharmacy Services Collaboration with AscellaHealth
Summit Reinsurance Services, Inc. announced a strategic collaboration with AscellaHealth, a pharmacy benefit manager offering innovative specialty drug programs developed as specialized solutions to the biggest drivers of pharmacy claims.
Read moreAre You Ready? Preparing for Gene and Cell Therapies Coming Down the Pipeline
Gene and cell therapies can be life changing but come with expensive price tags. As more therapies are FDA approved, payers are looking for options to control the spiraling cost of specialty pharmacy and to project future financial risk related to new therapies coming to market.
Read moreGene Therapy for Hemophilia A: Valrox may be the world’s most expensive one-time treatment
Should it be approved, BioMarin is considering pricing Valrox, a gene therapy drug aimed at hemophilia A, at $2 million to $3 million for the single treatment.
Read moreZolgensma and Gene Therapy: What is the Cost?
Gene therapy in healthcare has become a reality, and it is set to move from a trickle to a stream in the next few years. This article discusses Zolgensma and other emerging gene therapies in the context of how they may affect a health plan’s costs.
Read moreSummit Re Announces Collaboration with Deerwalk, Inc.
Summit Reinsurance Services, Inc. today announced a strategic collaboration with Deerwalk, Inc., an innovative population health management, data management, and healthcare analytics software company. Through this collaboration, Summit Re clients will have access to the most complete population health management suite in the industry. Efficient and accurate data collection, intake, enrichment, and reporting, will allow participating clients to obtain a full picture of their risk portfolio in order to make more effective management decisions.
Read more